When Dr Carl June of the University of Pennsylvania, used chimeric antigen receptor (CAR) technology to provide an amazing cure in a CAR-T trial in 2011 for three CLL patients that had pretty well run out of options
uphs.upenn.edu/news/News_Re...
there were valid concerns that the extremely high costs of this personalised form of immunotherapy would make it very difficult to translate into a readily available treatment option.
Nevertheless, efforts have continued to expand the ways in which this technology can be used and to find approaches to reduce the per patient cost. Here's a summary on these efforts from the 1-day Cancer Immunotherapy: A Long Awaited Reality Conference, held at the New York Academy of Medicine on March 27 on the different Engineered T-Cell Immunotherapy Approaches in Cancer:
cancernetwork.com/news/engi...
Neil